Literature DB >> 15015779

CD44 expression and tumour cell density correlate with response to tamoxifen/carboplatin chemotherapy in glioblastomas.

Christian Hagel1, Sung-Ho Park, Maximilian J A Puchner, Dimitrios Stavrou.   

Abstract

In order to identify response predictors for a post-operative glioblastoma therapy consisting of tamoxifen, carboplatin and radiotherapy, expression of 12 antigens was evaluated in 36 newly diagnosed tumours and 13 recurrences. Results were correlated with the clinical course of the disease. Antigen expression was assessed immunohistochemically for CD44s, TGF-beta2, TGF-alpha, progesterone receptor, estrogen receptor, EGFR, urokinase, urokinase inhibitor 1, CD87, p53 protein and Ki-67. Vessel density was determined by labelling of endothelia with von Willebrand factor. Response to chemotherapy correlated positively with cell density (p < 0.05) and negatively with CD44 over-expression (p < 0.02). Further, a positive correlation between age and CD44 expression (p < 0.05) and a negative correlation between age and p53 accumulation (p < 0.01) was found. In tumour recurrences expression of CD44 was significantly higher in local recurrences than in distant multifocal recurrences (p < 0.02), suggesting that CD44 may predominantly be associated with cell adhesion in glioblastomas.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15015779     DOI: 10.1023/b:neon.0000013496.58236.f0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  31 in total

1.  Surgery, tamoxifen, carboplatin, and radiotherapy in the treatment of newly diagnosed glioblastoma patients.

Authors:  M J Puchner; H D Herrmann; J Berger; L Cristante
Journal:  J Neurooncol       Date:  2000-09       Impact factor: 4.130

Review 2.  Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy.

Authors:  M Schmitt; N Harbeck; C Thomssen; O Wilhelm; V Magdolen; U Reuning; K Ulm; H Höfler; F Jänicke; H Graeff
Journal:  Thromb Haemost       Date:  1997-07       Impact factor: 5.249

3.  Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen.

Authors:  E Scarpi; F De Paola; M Sarti; P Bajorko; A M Granato; A Volpi; O Nanni; R Maltoni; D Amadori
Journal:  Breast Cancer Res Treat       Date:  2001-07       Impact factor: 4.872

4.  Tamoxifen-resistant glioma-cell sub-populations are characterized by increased migration and proliferation.

Authors:  M J Puchner; A Giese
Journal:  Int J Cancer       Date:  2000-05-15       Impact factor: 7.396

5.  Prognostic significance of endothelial surface score and MIB-1 labeling index in glioblastoma.

Authors:  J Vaquero; M Zurita; C Morales; S Oya; S Coca
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

6.  CD44 expression in astrocytic tumors.

Authors:  L R Ylagan; B Quinn
Journal:  Mod Pathol       Date:  1997-12       Impact factor: 7.842

7.  Immunohistochemical analysis of progesterone receptor and Ki-67 labeling index in astrocytic tumors.

Authors:  H Khalid; S Shibata; M Kishikawa; A Yasunaga; M Iseki; T Hiura
Journal:  Cancer       Date:  1997-12-01       Impact factor: 6.860

8.  Sex hormone receptors in intracranial tumours and normal brain.

Authors:  I R Whittle; R A Hawkins; J D Miller
Journal:  Eur J Surg Oncol       Date:  1987-08       Impact factor: 4.424

9.  Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen.

Authors:  W T Couldwell; M H Weiss; C M DeGiorgio; L P Weiner; D R Hinton; G R Ehresmann; P S Conti; M L Apuzzo
Journal:  Neurosurgery       Date:  1993-03       Impact factor: 4.654

10.  Implication of CD44 in adhesion-mediated overproduction of TGF-beta and IL-1 in monocytes from patients with bone marrow fibrosis.

Authors:  P Rameshwar; V T Chang; P Gascón
Journal:  Br J Haematol       Date:  1996-04       Impact factor: 6.998

View more
  2 in total

1.  Role of MIB1 in predicting survival in patients with glioblastomas.

Authors:  Shaye I Moskowitz; Tao Jin; Richard A Prayson
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

2.  Whole-genome approach implicates CD44 in cellular resistance to carboplatin.

Authors:  Sunita J Shukla; Shiwei Duan; Xiaolin Wu; Judith A Badner; Kristen Kasza; M Eileen Dolan
Journal:  Hum Genomics       Date:  2009-01       Impact factor: 4.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.